eMed's future growth in the surging GLP-1 market

Name: eMed's future growth in the surging GLP-1 market
Uploaded: 2026-03-26T12:46:41Z
Duration: 1 min 32 s

Mornings With Maria · FBN · Mar 26, 2026 · 1m 32s

Sign Up Now

Already a subscriber?

eMed CEO Linda Yaccarino discusses the significant growth potential for eMed within the expanding GLP-1 drug market. She emphasizes the transformative impact of AI on healthcare and the powerful role of GLP-1 medications, which have evolved from diabetes treatments to weight loss solutions and now show promise in chronic disease prevention and even combating addiction. Yaccarino positions eMed at the epicenter of this dynamic market shift.